Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc. Show more
5005 McConnell Avenue, Los Angeles, CA, 90066, United States
Market Cap
386.8M
52 Wk Range
$0.90 - $16.34
Previous Close
$10.56
Open
$10.56
Volume
22,947
Day Range
$10.18 - $10.73
Enterprise Value
666.2M
Cash
8.688M
Avg Qtr Burn
-6.674M
Insider Ownership
68.67%
Institutional Own.
3.39%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
AP-SA02 Details Bacterial infection | Phase 3 Initiation | |
AP-PA02 Details Non-Cystic Fibrosis Bronchiectasis | Phase 2 Update | |
AP-PA02 Details Cystic fibrosis | Phase 1/2 Update |
